CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas
Last updated: 01 Jan 2025
10.21608/zumj.2023.216665.2811
SMYD3, CDK9, serous ovarian carcinomas, prognosis, Immunohistochemistry
mona
mostafa
Zagazig university
mostafamona90@yahoo.com
0000-0003-2149-5439
Amr
Awd
A.
Obstetrics and Gynecology , Faculty of medicine, Zagazig University
amrawd75@yahoo.com
Amira
Elwan
Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Egypt
essawy1951@gmail.com
zagazig
0000-0003-2464-5113
DALIA
ELSAYED
HAMOUDA
MEDICAL ONCOLOGY FACULTY OF MEDICINE ZAGAZIG UNIVERSITY
hamoudadg@gmail.com
Sabah
Hanafy
mohamed
pathology department
drsabahmohamed@gmail.com
zagazig
29
6
44286
2023-11-01
2023-06-14
2023-11-01
1,497
1,505
1110-1431
2357-0717
https://zumj.journals.ekb.eg/article_310636.html
https://zumj.journals.ekb.eg/service?article_code=310636
310,636
Original Article
273
Journal
Zagazig University Medical Journal
https://zumj.journals.ekb.eg/
CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas
Details
Type
Article
Created At
30 Dec 2024